US5151267A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Bovine herpesvirus type 1 polypeptides and vaccines
Assignee: SASKATCHEWAN A CORP OF CANADA, University of
•
Filing: 1988-07-15
•
Granted: 1992-09-29
•
Expires: 2008-07-15
Abstract
Abstract Subunit vaccines against bovine herpesvirus type 1 are provided, as well as methods of vaccination and methods of making the subunit antigen employed in the vaccines.
Inventors
- 👤 Lorne Babiuk
- 👤 Sylvia van den Hurk
- 👤 Tim Zamb
- 👤 David Fitzpatrick
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-02 14:56
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/005; G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/68; G01N33/6854; A; A61; A61K; A61K39/00; C12; C12N; C12N2710/00; C12N2710/00011; C12N2710/16011; C12N2710/16711; C12N2710/16722; G01N2333/00; G01N2333/005; G01N2333/01; G01N2333/03
Claims Analysis
Total Claims: 18
Claim 1
Independent Claim
78 words
A method of protecting a bovine host from bovine herpesvirus type 1 (BHV-1) infection comprising: (a) providing a vaccine composition consisting essentially of (i) a pharmaceutically acceptable vehicle and (ii) at least one recombinant polypeptide comprising a polypeptide neutralizing epitope of a BHV-1 glycoprotein selected from the group consisting of gI, gIII, and gIV; and (b) administering an effective amount of said vaccine composition to said bovine host whereby neutralizing anti-BHV-1 antibodies are elicited in said bovine host.
Claim 2
Independent Claim
78 words
A method of protecting a bovine host from bovine herpesvirus type 1 (BHV-1) infection comprising: (a) providing a vaccine composition consisting essentially of (i) a pharmaceutically acceptable vehicle and (ii) at least one recombinant polypeptide comprising a polypeptide neutralizing epitope of a BHV-1 glycoprotein selected from the group consisting of gI, gIII, and gIV; and (b) administering an effective amount of said vaccine composition to said bovine host whereby neutralizing anti-BHV-1 antibodies are elicited in said bovine host.
Claim 3
Dependent Claim
13 words
The method of claim 1 wherein said vaccine composition further comprises an adjuvant.
Claim 4
Dependent Claim
11 words
The method of claim 1 wherein said BHV-1 glycoprotein is gI.
Claim 5
Dependent Claim
11 words
The method of claim 1 wherein said BHV-1 glycoprotein is gIII.
Claim 6
Dependent Claim
11 words
The method of claim 1 wherein said BHV-1 glycoprotein is gIV.
Claim 7
Dependent Claim
33 words
The method of claim 1 wherein said vaccine composition comprises at least two neutralizing epitopes form different BHV-1 glycoproteins, said different BHV-1 glycoproteins selected from the group consisting of gI, gIII and gIV.
Claim 8
Dependent Claim
15 words
The method of claim 6 wherein said two neutralizing epitopes are located on different polypeptides.
Claim 9
Dependent Claim
23 words
The method of claim 6 wherein one of said neutralizing epitopes is from gI and one of said neutralizing epitopes is from gIII.
Claim 10
Dependent Claim
23 words
The method of claim 6 wherein one of said neutralizing epitopes is from gI and one of said neutralizing epitopes is from gIV.
Claim 11
Dependent Claim
23 words
The method of claim 6 wherein one of said neutralizing epitopes is from gIII and one of said neutralizing epitopes is from gIV.
Claim 12
Dependent Claim
31 words
The method of claim 6 wherein one of said neutralizing epitopes is from gI, one of said neutralizing epitopes is from gIII, and one of said neutralizing epitopes is from gIV.
Claim 13
Dependent Claim
20 words
The method of claim 1 wherein said recombinant BHV-1 polypeptide is a recombinant polypeptide produced in a mammalian host cell.
Claim 14
Dependent Claim
21 words
The method of claim 12 wherein said mammalian host cell is transformed by a vaccinia virus vector encoding said recombinant polypeptide.
Claim 15
Dependent Claim
20 words
The method of claim 12 wherein said mammalian host cell is transformed by a SV40 vector encoding said recombinant polypeptide.
Claim 16
Dependent Claim
22 words
The method of claim 12 wherein said mammalian host cell is tranformed by a Rous sarcoma virus vector encoding said recombinant polypeptide.
Claim 17
Dependent Claim
11 words
The method of claim 1 wherein said subunit antigen is glycosylated.
Claim 18
Dependent Claim
12 words
The method of claim 1 wherein said subunit antigen is not glycosylated.
References Cited (Backward Citations)
GB1390468A
Cited
US4341784A
Cited
US4335105A
Cited
US4709011A
Cited
US4661349A
Cited
US4642333A
Cited
US4680176A
Cited
US4724146A
Cited
WO1988002634A1
Cited
EP0362531A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1995-09-29 | 1996-03-30 | 1996-09-29 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1999-09-29 | 2000-03-30 | 2000-09-29 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2003-09-29 | 2004-03-30 | 2004-09-29 | $7700.00 | Window Closed / Lapsed |